Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter

Entities Mentioned

• Volcano
• Scott Huennekens
• FDA

1. SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States. This state-of-the-art catheter offers all of the benefits of the predecessor Eagle Eye® Gold catheter, plus improved deliverability and the convenience of additional radiopaque markers. Commercial release of Eagle Eye® Platinum in the ... (Read Full Article)

   Bookmark or Share this article

   
   

   Related Articles

   • Spectral-domain OCT wows interventional cardiologists
   • also categorized in Cardiology
   • Volcano Announces Agreement to Acquire CardioSpectra
   • also mentions Volcano
   • Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: do uncovered struts persist?
   • also categorized in Cardiology
   • Volcano Announces Closing of CardioSpectra Acquisition
   • also categorized in Cardiology
   • IVUS Disposable Revenues Increase 46 Percent
   • also categorized in Cardiology

   • Quantitative analysis on optical properties of human atherosclerosis by using polarization-sensitive optical coherence tomography
   • also categorized in Cardiology
   • Super-Thin Drug-Free Coating 'Hides' Stent as It Unblocks Heart ...
   • also published in PR Newswire
   • Vision Researchers Query FDA About Updating Requirements For Drug Approval
   • also mentions FDA
   • Spinoff Company’s Sale Hailed as Coup for Texas, San Antonio Biotech
   • also categorized in Cardiology
   • Volcano Announces Agreement to Acquire CardioSpectra
   • also published in PR Newswire

Login to comment.